Luca Fischer, Linmiao Jiang, Jan Dürig, Christian Schmidt, Stephan Stilgenbauer, Krimo Bouabdallah, Philippe Solal-Celigny, Christian W Scholz, Pierre Feugier, Maike de Wit, Ralf Ulrich Trappe, Michael Hallek, Ullrich Graeven, Mathias Hänel, Martin Hoffmann, Vincent Delwail, Margaret Macro, Jochen Greiner, Aristoteles A N Giagounidis, Beate Dargel, Eric Durot, Charles Foussard, Elisabeth Silkenstedt, Oliver Weigert, Christiane Pott, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Vincent Ribrag, Martin Dreyling
The therapy of relapsed or refractory (r/r) mantle cell lymphoma (MCL) patients remains a major clinical challenge to date. We conducted a randomized, open-label, parallel-group phase-III trial hypothesizing superior efficacy of rituximab, high-dose cytarabine and dexamethasone with bortezomib (R-HAD + B) versus without (R-HAD) in r/r MCL ineligible for or relapsed after autologous stem cell transplant (ASCT). Primary endpoint was time to treatment failure (TTF), secondary endpoints included response rates, progression free survival, overall survival, and safety...
April 27, 2024: Leukemia